These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

899 related items for PubMed ID: 33455920

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Determinants of COVID-19 disease severity in patients with underlying rheumatic disease.
    Santos CS, Morales CM, Álvarez ED, Castro CÁ, Robles AL, Sandoval TP.
    Clin Rheumatol; 2020 Sep; 39(9):2789-2796. PubMed ID: 32720259
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Evaluation of the frequency and intensity of COVID-19 in patients with ankylosing spondylitis under anti-TNF therapy.
    Türk SM, Öztürk Z, Karataş D, Erkorkmaz Ü, Gönüllü E.
    Turk J Med Sci; 2022 Apr; 52(2):522-523. PubMed ID: 36161620
    [Abstract] [Full Text] [Related]

  • 8. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
    Garcia-Vicuña R, Abad-Santos F, González-Alvaro I, Ramos-Lima F, Sanz JS.
    Trials; 2020 Sep 09; 21(1):772. PubMed ID: 32907638
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules: A multicentre retrospective study.
    Sarzi-Puttini P, Marotto D, Caporali R, Montecucco CM, Favalli EG, Franceschini F, Fredi M, Balduzzi S, Bazzani C, Bongiovanni S, Giorgi V, Batticciotto A, Cappelli A, Balzarini P, Dagna L, Sartorelli S, Ravagnani V, Tamanini S, Farah S, Faggioli P, Castelnovo L, Lurati AM, Galli M, Salaffi F.
    J Autoimmun; 2021 Jan 09; 116():102545. PubMed ID: 32972804
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Immuno-inflammatory rheumatic diseases and COVID-19: analysis of clinical outcomes according to the data of the register of patients of the Novosibirsk region receiving therapy with genetically engineered biological drugs].
    Korolev MA, Letyagina EA, Sizikov AE, Bogoderova LA, Ubshaeva YB, Omelchenko VO, Akimova AA, Mullagaliev AA, Chumasova OA, Kurochkina YD.
    Ter Arkh; 2022 Jun 17; 94(5):636-641. PubMed ID: 36286962
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Role of targeted therapies in rheumatic patients on COVID-19 outcomes: results from the COVIDSER study.
    Álvaro Gracia JM, Sanchez-Piedra C, Manero J, Ruiz-Lucea ME, López-Vives L, Bohorquez C, Martinez-Barrio J, Bonilla G, Vela P, García-Villanueva MJ, Navío-Marco MT, Pavía M, Galindo M, Erausquin C, Gonzalez-Gay MA, Rua-Figueroa I, Pego-Reigosa JM, Castrejon I, Sanchez-Costa JT, González-Dávila E, Diaz-Gonzalez F, COVIDSER study group.
    RMD Open; 2021 Dec 17; 7(3):. PubMed ID: 34887346
    [Abstract] [Full Text] [Related]

  • 17. Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies.
    Sanchez-Piedra C, Diaz-Torne C, Manero J, Pego-Reigosa JM, Rúa-Figueroa Í, Gonzalez-Gay MA, Gomez-Reino J, Alvaro-Gracia JM, BIOBADASER study group.
    Ann Rheum Dis; 2020 Jul 17; 79(7):988-990. PubMed ID: 32503857
    [No Abstract] [Full Text] [Related]

  • 18. Effectiveness of a fourth dose of COVID-19 mRNA vaccine in patients with systemic autoimmune rheumatic diseases using disease-modifying antirheumatic drugs: an emulated target trial.
    Hanberg JS, Fu X, Wang X, Patel NJ, Kawano Y, Schiff A, Kowalski EN, Cook CE, Vanni KMM, Guzzo K, Qian G, Bade KJ, Saavedra A, Venkat R, Srivatsan S, Zhang Y, Sparks JA, Wallace ZS.
    Lancet Rheumatol; 2024 Jan 17; 6(1):e21-e30. PubMed ID: 38258675
    [Abstract] [Full Text] [Related]

  • 19. Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases.
    Hasseli R, Mueller-Ladner U, Hoyer BF, Krause A, Lorenz HM, Pfeil A, Richter J, Schäfer M, Schmeiser T, Strangfeld A, Schulze-Koops H, Voll RE, Specker C, Regierer AC.
    RMD Open; 2021 Jan 17; 7(1):. PubMed ID: 33479021
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.